These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 29730950)

  • 61. Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
    Zhuo C; Li X; Zhuang H; Tian S; Cui H; Jiang R; Liu C; Tao R; Lin X
    Oncotarget; 2016 Dec; 7(50):82567-82579. PubMed ID: 27788495
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].
    Rouprêt M; Neuzillet Y; Larré S; Pignot G; Coloby P; Rébillard X; Mongiat-Artus P; Chartier-Kastler E; Soulié M; Pfister C;
    Prog Urol; 2012 Nov; 22(15):920-31. PubMed ID: 23102014
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
    [TBL] [Abstract][Full Text] [Related]  

  • 64. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.
    Kamat AM; Colombel M; Sundi D; Lamm D; Boehle A; Brausi M; Buckley R; Persad R; Palou J; Soloway M; Witjes JA
    Nat Rev Urol; 2017 Apr; 14(4):244-255. PubMed ID: 28248951
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette-Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis.
    Wu C; Zhou X; Miao C; Zhang J; Tang Q; Chang X; Ni H
    Cell Physiol Biochem; 2017; 41(4):1298-1312. PubMed ID: 28278504
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
    Mukherjee N; Svatek RS; Mansour AM
    Urol Oncol; 2018 Mar; 36(3):103-108. PubMed ID: 29429897
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
    Nykopp TK; Batista da Costa J; Mannas M; Black PC
    Curr Urol Rep; 2018 Oct; 19(12):101. PubMed ID: 30357541
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert's panel. Spanish Association of Urology.
    Fernández-Gómez JM; Carballido-Rodríguez J; Cozar-Olmo JM; Palou-Redorta J; Solsona-Narbón E; Unda-Urzaiz JM;
    Actas Urol Esp; 2013; 37(7):387-94. PubMed ID: 23773824
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.].
    Coenen JJMJH; van Valenberg FJP; Arends TJH; Witjes JA
    Arch Esp Urol; 2018 May; 71(4):400-408. PubMed ID: 29745929
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Updates on intravesical therapy.
    Pisano F; Vila Reyes H; Breda A; Palou J
    Curr Opin Urol; 2019 Nov; 29(6):649-655. PubMed ID: 31567439
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage.
    Fankhauser CD; Teoh JY; Mostafid H
    Curr Opin Urol; 2020 May; 30(3):365-369. PubMed ID: 32141939
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
    Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
    BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.
    Sylvester RJ
    Int J Urol; 2011 Feb; 18(2):113-20. PubMed ID: 21091799
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses.
    Shelley MD; Mason MD; Kynaston H
    Cancer Treat Rev; 2010 May; 36(3):195-205. PubMed ID: 20079574
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
    Kaasinen E; Rintala E; Pere AK; Kallio J; Puolakka VM; Liukkonen T; Tuhkanen K
    J Urol; 2000 Jul; 164(1):47-52. PubMed ID: 10840422
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study.
    Soria F; Milla P; Fiorito C; Pisano F; Sogni F; Di Marco M; Pagliarulo V; Dosio F; Gontero P
    World J Urol; 2016 Feb; 34(2):189-95. PubMed ID: 26026818
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bladder cancer: current optimal intravesical treatment.
    Lamm DL; McGee WR; Hale K
    Urol Nurs; 2005 Oct; 25(5):323-6, 331-2. PubMed ID: 16294610
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
    Barlow LJ; McKiernan JM; Benson MC
    J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.